Оценка риска поражения мышечной ткани при терапии статинами
Диссертация
Значимыми предикторами статин-ассоциированного поражения мышечной ткани являются: длительность гиполипидемической терапии 12 месяцев и более (отношение шансов 7,7, р=0,0002), прием аторвастатина в дозе 40 мг/сут и более (отношение шансов 2,67, р=0,0139). Отмечена тенденция более частых статин-ассоциированных мышечных явлений у женщин (отношение шансов 1,88, р=0,23) и носителей аллельного варианта… Читать ещё >
Список литературы
- Алгоритм Наранжо для оценки причинно-следственной связи «НПР-лекарство» Электронный ресурс. // Федеральная служба по надзору в сфере здравоохранения: [сайт]. -Режим доступа: http://www.roszdravnadzor.ni/tests/l (дата обращения:01.06.2012).
- Боль: руководство для врачей и студентов / под ред. акад. РАМН Н. Н. Яхно. М.: МЕДпрессинформ, 2009. — 304 с.: ил.
- Кобалава, Ж. Д. Безопасность статинов: реальное и надуманное / Ж. Д. Кобалава, С. В. Виллевальде, Е. К. Шаварова // Кардиоваскулярная терапия и профилактика. 2007. — Т. 6, № 2. — С. 105−112.
- Определение степени достоверности причинно-следственной связи «неблагоприятная лекарственная реакция — лекарственное средство»: методические рекомендации / Федеральная служба по надзору в сфере здравоохранения и социального развития. М., 2008. — 14 с.
- Смусева, О. Н. Мониторинг безопасности лекарственных средств: оценка роли практических врачей / О. Н Смусева, Ю. В. Соловкина // Астраханский медицинский журнал. -2012. -№ 1. С. 104−107.
- A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study / J. S. Macdonald et al. // Invest New Drugs. 2005. — Vol. 23. — P. 485187.
- A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis / P. S. Kruger et al. // Intensive Care Med. 2009. — Vol. 35. — P. 717−721.
- Abd, T. T. Statin-induced myopathy: a review and update / T. T. Abd, T. A. Jacobson // Expert Opin Drug Saf. 2011. — May, N 10. — P. 373−387.
- Abeles, A. M. Statins as antiinfl ammatory and immunomodulatory agents: a future in rheumatologic therapy? / A. M. Abeles, M. H. Pillinger // Arthritis & Rheumatism. 2006. — Vol. 54, is. 2. — P. 393107.
- ACC/AHA/NHLBI clinical advisory on the use and safety of statins / R. C. Pasternak et al. //J Am College of Cardiology. 2002. — Vol. 40. — P. 567−572.
- ACC/AHA/NHLBI clinical advisory on the use and safety of statins / R. C. et al. — American College of Cardiology // J Am Coll Cardiol. 2002. — Vol. 40. -P. 567−572.
- Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? / V. G. Athyros et al. // Curr Opin Cardiol. -2010.-Vol. 25.-P. 406−410.
- Almog, Y. Statins, inflammation, and sepsis: Hypothesis / Y. Almog // Chest.2003. Vol. 124. — P. 740−743.
- Amarenco, P. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention / P. Amarenco, J. Labreuche // Lancet Neurol. 2009. — Vol. 8. — P. 453−463.
- Analyses of cancer data from three ezetimibe trials / R. Peto et al. // N Engl J Med. 2008. — Vol. 359. — P. 1357−1366.
- Anderson, D. C. Review: Statins do not increase risk for intracerebral hemorrhage / D. Anderson // Ann Intern Med. 2012. — Vol. 156, N 6. — P. 3−6.
- Appendix 4 // The Global Use of Medicines: Outlook Through 2015 / Aitken M. for IMS Institute for Healthcare Informatics. 2011. — May. — P. 26.
- Armitage, J. The safety of statins in clinical practice / J. Armitage // Lancet. -2007. Vol. 370. — P. 1781−1790.
- Armitage, J. The safety of statins in clinical practice / J. Armitage // Lancet. -2007.-Vol. 370.-P. 1781−1790.-DOT 10.1016/SO 140−6736(07)60716−8.
- Association between statin-associated myopathy and skeletal muscle damage / M. G. Mohaupt et al. // CMAJ. 2009. — Vol. 181, N ½. — El 1-E18.
- Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups / D. L. Tirschwell et al. // Neurology. 2004. — Vol. 63. — P. 18 681 875.
- Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab / W. De Roock et al. // JAMA. -2011. Vol. 304.-P. 1812−1820.
- Association of statin use and development and progression of hip osteoarthritis in elderly women / M. S. Beattie et al. // J Rheumatol. 2005. — Vol. 32. — P. 106 110.
- Atorvastatin and pravastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice / T. Kurata et al. // Brain Res. 2011. -Vol. 1371.-P. 161−170.-DOI 10.1016/j.brainres.2010.11.067.
- Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease / H. F. Alber et al. // J Am Coll Cardiol. 2002. — Vol. 39.-P. 1951−1955.
- Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis / T. T. Tang et al. // J Lipid Res. 2011. -Vol. 52.-P. 1023−1032.
- Atorvastatin: safety and tolerability / V. G. Athyros et al. // Expert Opin Drug Saf. 2010. — Vol. 9. — P. 667−674.
- Baker, J. F. Statins: a potential role in the management of osteoarthritis? / J. F. Baker, P. Walsh, K. J. Mulhall // Joint Bone Spine. 2011. — Vol. 78. — P. 31−34.
- Bays, H. Statin safety: an overview and assessment of the data-2005 / H. Bays // Am J Cardiol. 2006. — Vol. 97. — 6 C-26 C.
- Bellosta, S. Safety of statins: focus on clinical pharmacokinetics and drug interactions / S. Bellosta, R. Paoletti, A. Corsini // Circulation. 2004. — Vol. 109, (suppl. III).-P. 50−57.
- Beltowski, J. Adverse effects of statins—mechanisms and consequences / J. Beltowski, G. Wojcicka, A. Jamroz-Wisniewska // Curr Drug Saf 2009. — Vol. 4. — P. 209−228.
- Ben-Yehuda, O. Low LDL-C levels and cancer reassuring but still not definitive / O. Ben-Yehuda, A. N. DeMaria // J Am Coll Cardiol. 2008. — Vol. 52. — P. 1150−1151.
- Bjerre, L. M. Do statins cause cancer? A meta-analysis of large randomized clinical trials / L. M. Bjerre, J. LeLorier // Am J Med. 2001. — Vol. 110. — P. 716−723.
- Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis / J. Wu et al. // Cancer Res. 2004. — Vol. 64.-P. 6461−6468.
- Bottorff, M. B. Statin safety and drug interactions: clinical implications / M. B. Bottorff// Am J Cardiol. 2006. — Vol. 97. — 27 C-31 C.
- Brass, L. M. An assessment of statin safety by neurologists / L. M. Brass, M. J. Alberts, L. Sparks // Am J Cardiol. 2006. — Vol. 97. — 86C-88C. — DOI 10.1016/j.amjcard.2005.12.017.
- Brewer, H. B. Jr. Benefit-risk assessment of rosuvastatin 10 to 40 miligrams / H. B. Jr. Brewer // Am J Cardiol. 2003. — Vol. 92. — P. 23−29.
- Brower, V. Of Cancer and cholesterol: studies elucidate anticancer mechanisms of statins / V. Brower // J Natl Cancer Inst. 2003. — Vol. 95. — P. 844−846.
- Brown, W. V. Safety of statins / W. V. Brown // Curr Opin Lipidol. 2008. -Vol. 19.-P. 558−562.
- Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy / S. D. Wiviott et al. // J Am Coll Cardiol. 2005. — Vol. 46. -P. 1411−1416.
- Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations / J. Genest et al. // Can J Cardiol. 2009. — Vol. 25. — P. 567−579.
- Cancer risk among statin users: a population-based cohort study / S. Friis et al. // Int J Cancer. 2005. — Vol. 114. — P. 643−647.
- Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial / P. Ridker et al. // The Lancet. 2012. -Vol. 380, N 9841. — P. 565−571.
- Cardiovascular medication use and risk for colorectal cancer / D. M. Boudreau et al. // Cancer Epidemiol Biomarkers Prev. 2008. — Vol. 17. — P. 3076−3080.
- Casey, P. J. Protein lipidation in cell signaling / P. J. Casey // Science. 1995. -Vol. 268.-P. 221−225.
- Chan, K. K. The statins as anticancer agents / K. K. Chan, A. M. Oza, L. L. Siu // Clin Cancer Res. 2003. — Vol. 9. — P. 10−19.
- Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins // Lancet. 2005. — Vol. 366. — P. 1267−1278.
- Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort / E. J. Jacobs et al. // J Natl Cancer Tnst. 2006. — Vol. 98. — P. 69−72.
- Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials/ De Caterina R. et al. // J Am Coll Cardiol. — 2010. -Vol. 55.-P. 198−211.
- Chronic statin therapy and the risk of colorectal cancer / Y. X. Yang et al. // Pharmacoepidemiol Drug Saf. 2008. — Vol. 17. — P. 869−876.
- Clark, T. G. Quantification of the completeness of follow-up / T. G. Clark, D. G. Altaian, B. L. De Stavola // Lancet. 2002. — Vol. 359. — P. 1309−1310.
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy / F. Di Fiore et al. // Br J Cancer. -2007. Vol. 96. — P. 1166−1169.
- Cognitive impairment associated with atorvastatin and simvastatin / D. S. King etal. //Pharmacotherapy. -2003. Vol. 23. — P. 1663−1667.
- Common nonsynonymous substitutions in SLCOIBI predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study / L. A. Donnelly et al. // Clin Pharmacol Ther. 2011. — Vol. 89. — P. 210−216.
- Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients / C. Newman et al. // Am J Cardiol. -2006.-Vol. 97.-P. 61−67.
- Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering / M. J. Pletchter et al. // Ann Intern Med. 2009. — Vol. 150. — P. 243−254.
- Comparison of GE Centricity Electronic Medical Record Database and National Ambulatory Medical Care Survey Findings on the prevalence of major conditions in the United States / A. Crawford et al. // Popul Health Manag. 2010. — Vol. 13.-P. 139−150.
- Conaghan, P. G. The Effects of Statins on Osteoarthritis Structural Progression / P. G. Conaghan // Ann Rheum Dis. 2012. — Vol. 71. — P. 633−634.
- Conceptual foundations of the UCSD statin study. / B. Golomb et al. // Arch Intern Med. 2004. — Vol. 164.-P. 153−162.
- Coogan, P. F. Statin use and risk of colorectal cancer / P. F. Coogan, J. Smith, L. Rosenberg // J Natl Cancer Inst. 2007. — Vol. 99. — P. 32−40.
- Corsini, A. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? / A. Corsini, R. Ceska // Curr Med Res Opin. 2011. -Vol. 27.-P. 1551−1562.
- C-reactive protein levels and outcomes after statin therapy / P. M. Ridker et al. // N Engl J Med. 2005. — Vol. 352, N 1. — P. 20−28.
- D’Agostino, R. B. Estimating and using propensity scores with partially missing data / R. B. D’Agostino, D. B. Rubin // J Am Stat Assoc. 2000. — Vol. 95. — P. 749−759.
- Davidson, M. H. Combination therapy for dyslipidemia: safety and regulatory considerations / M. H. Davidson // Am J Cardiol. 2002. — Vol. 90. — 50K-60K.
- DeMaria, A. N. Low-density lipoprotein reduction and cancer: not definitive but provocative / A. N. DeMaria, O. Ben-Yehuda // J Am Coll Cardiol. 2007. -Vol. 50.-P. 421—422.
- Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study / P. Amarenco et al. // Cerebrovasc Dis. 2003. — Vol. 16. — P. 389−395.
- Di Paolo, G. Linking lipids to Alzheimer’s disease: cholesterol and beyond / G. Di Paolo, T. W. Kim // Nat Rev Neurosci. 2011. — Vol. 12. — P. 284−296.
- Do low dose statins affect cognition? Results of the UCSD statin study / B. A. Golomb et al. // Circulation. 2006. — Vol. 114, II. — P. 289.
- Does simvastatin cause more myotoxicity compared with other statins? / J. M. Backes et al. // Ann Pharmacother. 2009. — Vol. 43. — P. 2012−2020.
- Effect of atorvastatin on cognitive function in patients from the lipid lowering and onset of renal disease (LORD) trial / M. J. Summers et al. // Pharmacotherapy. 2007. — Vol. 27. — P. 183−190. — DOI 10.1592/phco.27.2.183.
- Effect of coenzyme Q (10) supplementation on simvastatin-induced myalgia / J. M. Young et al. // Am J Cardiol. 2007. — Vol. 100. — P. 1400−1403.
- Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin /1. F. Gazi et al. // Curr Med Res Opin. 2007. — Vol. 23. — P. 2183 — 2192.
- Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial / P. L. Thompson et al. // Am Heart J. 2004. — Vol. 148. — P. 2.
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial // Lancet. 2008. — Vol. 372. -P. 1231−1239.
- Effect of Statins on Skeletal Muscle Function / B. A. Parker et al. // Circulation.- 2013. Vol. 127. — P. 96−103.
- Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer insights from large randomized statin trials / A. Alsheikh-Ali et al. // J Am Coll Cardiol. 2007. — Vol. 50. — P. 409−418.
- Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance / J. M. Backes et al. // Ann Pharmacother. 2008. -Vol. 42.-P. 341−346.
- Effects of atorvastatin on higher functions / G. P. Parale et al. // Eur J Clin Pharmacol. 2006. — Vol. 62. — P. 259−265. — DOI 10.1007/s00228−005−0073-z.
- Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease / J. L. Perez-Castrillon et al. // Am J Cardiol. 2007. — Vol. 99. — P. 903−905.
- Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions / R. Collins et al. // Lancet. 2004. — Vol. 363. — P. 757−767.
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial / A. Keech et al. // Lancet. 2005. — Vol. 366. — P. 1849−1861.
- Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Thl/Th2 and CD4/CD8 ratios / H. Kanda et al. // Mod Rheumatol. 2007. -Vol. 17. — P. 364−368.
- Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic «metastases» in vivo / S. A. Broitman et al. // Adv Exp Med Biol.- 1996.-Vol. 401.-P. 111−130.
- Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial / A. P. Maggionil et al. // European Heart Journal. 2009. -Vol. 30. — P. 2327−2336.
- Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults / J. V. Agostini et al. // J Am Geriatr Soc. 2007. — Vol. 55. — P. 420−425.-DOI 10.111 l/j, 1532−5415.2007.1 071.x.
- Effects of Statins on Energy and Fatigue With Exertion: Results From a Randomized Controlled Trial / B. Golomb et al. // Arch Intern Med. 2012. -Vol. 172.-P. 1180−1182. -doi:10.1001/archinternmed.2012.2171.
- Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects / D. Bunout et al. // Exp Gerontol. 2006. — Vol. 41. — P. 746−752.
- Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins / C. Baigent et al. // Lancet. 2005. — Vol. 366. — P. 1267−1278.
- Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins / C. Baigent et al. // Lancet. 2005. — Vol. 366. — P. 1267−1278.
- Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials./ C. Baigent et al. // Lancet. 2010. — Vol. 376. — P. 1670−1681.
- Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis / P. M. Kearney et al. // Lancet. -2008.-Vol. 371.-P. 117−125.
- Elliott, W. J. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis / W. J. Elliot, P. M. Meyer // Lancet. 2007. — Vol. 369. -P. 201−207.
- Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project / D. Zhao et al. // Stroke. 2008. — Vol. 39. — P. 1668−1674.
- ESC/EAS Guidelines for the management of dyslipidaemias // European Heart Journal. -2011. -Vol. 32.-P. 176^-1818.
- Evans, M. A. Statin-associated adverse cognitive effects: survey results from 171 patients / M. A. Evans, B. A. Golomb // Pharmacotherapy. 2009. -Vol. 29.-P. 800−811.
- Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab / S. Khambata-Ford et al. // J Clin Oncol. 2007. — Vol. 25. — P. 3230−3237.
- FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs Электронный ресурс. // FDA: [сайт]. 2012. — Режим доступа: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (дата обращения: 10.10.2012).
- FDA’s Sentinel Initiative Электронный ресурс. 11 FDA: [сайт]. 2010. -7 февр. — Режим доступа: http://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm (дата обращения: 10.10.2012).
- Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial / P. W. Serruys et al. // JAMA. 2002. — Vol. 287. — P. 3215−3222.
- For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes / A. A. Siddiqui et al. // Dig Dis Sci. -2009.-Vol. 54.-P. 1307−1311.
- Frishman, W. H. Statin-drug interactions: not a class effect / W. H. Frisman, J. Horn // Cardiol Rev. 2008. — Vol. 16. — P. 205−212.
- From vulnerable plaque to vulnerable patient—Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report / M. Naghavi et al. // Am J Cardiol. 2006. — Vol. 98. — 2H-15H.
- Fung, E. C. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge / E. C. Fung, M. A. Crook // Cardiovasc Ther. 2011. — 1 April. — Epub ahead of print.
- Genetic determinants of statin intolerance / J. Oh et al. // Lipids Health Dis.-2007.-Vol. 6.-P. 7.
- Genetic risk factors associated with lipid-lowering drug-induced myopathies / G. D. Vladutiu et al. // Muscle Nerve. 2006. — Vol. 34. — P. 153— 162.
- Gillett, R. C. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicitiy / R. C. Gillett, A. Norrell // Am Fam Physician.-2011.-Vol. 83.-P. 711−716.
- Goldstein, J. L. Regulation of the mevalonate pathway / J. L. Goldstein, M. S. Brown II Nature. 1990. — Vol. 343. — P. 425−430.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial // Lancet. 2002. — Vol. 360. — P. 7−22.
- Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study / L. B. Goldstein et al. // Neurology. 2008. — Vol. 70. — P. 2364−2370.
- High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors / M. Z. Erkal et al. // Osteoporos Int. 2006. — Vol. 17. — P. 11 331 140.
- High-dose atorvastatin after stroke or transient ischemic attack / P. Amarenco et al. // N Engl J Med. 2006. — Vol. 355. — P. 549−559.
- High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study / T. R. Pedersen et al. // JAMA. -2005. Vol. 294. — P. 2437−2445.
- Holtzman, С. W. Role of P-glycoprotein in statin drug interactions / C. W. Holtzman, B. S. Wiggins, S. A. Spinier // Pharmacotherapy. 2006. — Vol. 26. -P. 1601−1607.
- Ни, M. Safety of Statins / M. Ни, В. M. Y. Cheung, B. Tomlinson // Therapeutic Advances in Drug Safety. -2012. Vol. 3. — P. 133−144.
- Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89 803 / J. A. Meyerhardt et al. // J Clin Oncol. 2006. — Vol. 24. — P. 3535−3541.
- IMS Health. Top 20 Global Therapeutic Classes, 2011, Total Audited Markets. 2011 Электронный ресурс. — Режим доступа: http://www.imshealtli.com (дата обращения: 10.10.2012).
- Increasedlevels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatintreatment: a novel pleiotropic effect of statins? / B. Yavuz et al. // Cardiovasc Drugs Ther. 2009. — Vol. 23. — P. 295−299.
- Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Thl development and promotes Th2 development / R. Hakamada-Taguchi et al. // Circ Res. -2003. Vol. 93. — P. 948−956.
- Insull, W. Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review / W. Jr. Insull // South Med J. — 2006. Vol. 99. — P. 257−273.
- Intensive lipid lowering with atorvastatin in patients with stable coronary disease / J. C. LaRosa et al. // N Engl J Med. 2005. — Vol. 352. — P. 14 251 435.
- Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis / A. B. Rossebo et al. // N Engl J Med. 2008. — Vol. 359. — P. 1343−1356.
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial / J. Armitage et al. // Lancet. 2010. — Vol. 376. — P. 16 581 669.
- Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89 803 / L. B. Saltz et al. // J Clin Oncol. 2007. — Vol. 25. — P. 34 563 461.
- Tsaacs, L. L. Evaluating anecdotes and case reports / L. L. Isaacs // Altern Ther Health Med. 2007. — Vol. 13. — P. 36−38.
- Jacobson, T. A. Myopathy with statin-fibrate combination therapy: clinical considerations / T. A. Jacobson // Nat Rev Endocrinol. 2009. — Vol. 5. — P. 507−518.
- Jones, M. P. A general class of nonparametric tests for survival analysis / M. A. Jones, J. Crowley// Biometrics. 1989. — Vol. 45. — P. 157−170.
- Josan, K. The efficacy and safety of intensive statin therapy: a metaanalysis of randomized trials / K. Josan, S. R. Majumdar, F. A. McAlister // CMAJ. 2008. — Vol. 178. — P. 576−584.
- Joy, T. R. Narrative review: statin-related myopathy / T. R. Joy, R. A. Hegele // Ann Intern Med. 2009. — Vol. 150. — P. 858−868.
- Kalliokoski, A. Impact of OATP transporters on pharmacokinetics / A. Kalliokoski, M. Niemi // Br J Pharmacol. 2009. — Vol. 158, N 3. — P. 693−705.
- Kaplan, E. L. Nonparametric estimation from incomplete observations / E. L. Kaplan, P. Meier// J Am Stat Assoc. 1958. — Vol. 53. — P. 457−481.
- Katz, M. S. Therapy insight: potential of statins for cancer chemoprevention and therapy / M. S. Katz // Nature Clin Pract Oncol. 2005. -Vol. 2. — P. 82−89.
- Kaye, J. A. Statin use and cancer risk in the General Practice Research Database / J. A. Kaye, H. Jick // Br J Cancer. 2004. — Vol. 90. — P. 635−637.
- Kleinbaum, D. G. Survival Analysis: A Self-Learning Text / D. G. Kleinbaum, M. Klein. 2nd ed. — New York: Springer Science + Business Media, LLC, 2005. — 590 p.
- KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89 803 / S. Ogino et al. // Clin Cancer Res. 2009. -Vol. 15.-P. 7322−7329.
- KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer / A. Lievre et al. // Cancer Res. 2006. — Vol. 66. — P. 39 923 995.
- Langsjoen, P. H. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications / P. H. Langsjoen, A. M. Langsjoen // Biofactors. 2003. — Vol. 18. -P. 101−111.
- Law, M. R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis / M. R. Law, N. J. Wald, A. R. Rudnicka // BMJ. 2003. — Vol. 326. -P. 1423.
- Law, M. Statin safety: a systematic review / M. Law, A. R. Rudnicka // Am J Cardiol. 2006. — Vol. 97. — 52C-60C.
- Lee, P. Vitamin D insufficiency-a novel mechanism of statin-induced myalgia? / P. Lee, J. R. Greenfield, L. V. Campbell // Clin Endocrinol (Oxf). -2009. Vol. 71.-P. 154−155.
- Lefer, A. M. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease / A. M. Lefer, R. Scalia, D. J. Lefer // Cardio vase Res. 2001. — Vol. 49. — P. 281 287.
- Life long changes in cognitive ability are associated with prescribed medications in old age / J. M, Starr et al. // Int J Geriatr Psychiatry. 2004. -Vol. 19. — P. 327−332.
- Lipid-lowering drugs and risk of myopathy: a population-based follow-up study/ D. Gaist C. et al. // Epidemiology. 2001. — Vol. 12. — P. 565−569.
- Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation / M. J. Barter et al. // Ann Rheum Dis. 2010. — Vol. 69. — P. 2189−2198.
- Long-term use of statins and risk of colorectal cancer: a population-based study / H. Singh et al. // Am J Gastroenterol. 2009. — Vol. 104. — P. 30 153 023.
- Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells / B. Agarwal et al. // Clin Cancer Res. 1999. — Vol. 5. — P. 2223−2229.
- Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion / T. Nubel et al. // FASEB J. 2004. — Vol. 18.-P. 140−142.
- Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase / S. Rao et al. // Proc Natl Acad Sci USA. 1999. — Vol. 96. — P. 7797−7802.
- Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients / W. Ahmed et al. // Transl Res.-2009.-Vol. 153.-P. 11−16.
- Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study / H. Noda et al. // Circulation. 2009. — Vol. 119. — P. 2136−2145.
- Marcoff^ L. The role of coenzyme Q10 in statin-associated myopathy: a systematic review / L. Marcoff, P. D. Thompson // J Am Coll Cardiol. 2007. -Vol. 49.-P. 2231−2237.
- Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! / R. Y. Gordon et al. // Arch Intern Med. 2010. — Vol. 170.-P. 1722−1727.
- McGowan, M. P. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients / M. P. McGowan // Circulation. 2004. — Vol. 110. — P. 2333−2335.
- Medicines: safety of medicines adverse drug reactions Электронный ресурс. // World Health Organization: [сайт]. — 2013. — Режим доступа: http://www.who.int/mediacentre/factsheets/fs293/en/ (дата обращения: 05.05.13).
- Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial infl animation / Y. Akasaki et al. // Osteoarthr Cartil. 2009. — Vol. 17. — P. 235−243.
- Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study/ E. Bruckert et al. // Cardiovasc Drugs Ther. 2005. — Vol. 19. — P. 403−414.
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial // Lancet. -2002. Vol. 360. — P. 7−22.
- Muangpaisan, W. Systematic review of statins for the prevention of vascular dementia or dementia / W. Muangpaisan, C. Brayne // Geriatr Gerontol Int.-2010.-Vol. 10.-P. 199−208.
- Musso, G. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update / G. Musso, M. Cassader, R. Gambino // Curr Opin Lipidol. 2011. — Vol. 22. — P. 489196.
- National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force / J. M. McKenney et al. // Am J Cardiol. 2006. — Vol. 97. — 89C-94C.
- Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo / S. Klopfleisch et al. // J Neurosci. 2008. — Vol. 28. — P. 13 609−13 614.
- Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer / D. J. Robertson et al. // Clin Gastroenterol Hepatol. -2010. Vol. 8. — P. 1056−1061.
- Neuvonen, P. J. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance / P. J. Neuvonen, M. Niemi, J. T. Backman // Clin Pharmacol Ther. 2006. — Vol. 80, N 6. — P. 565−581.
- Niemi, M. SLCOIBI polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin / M. Niemi, M. K. Pasanen, P. J. Neuvonen // Clinical Pharm Ther. 2006. — Vol. 80. — P. 356−366.
- Niemi, M. Transporter Pharmacogenetics and Statin Toxicity / M. Niemi // Clinical Pharm Ther. 2009. — Vol. 87. — P. 130−133.
- Omar, M. A. FDA adverse event reports on statin-associated rhabdomyolysis / M. A. Omar, J. P. Wilson // Ann Pharmacother. 2002. — Vol. 36.-P. 288−295.
- Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies / S. Benvenuti et al. // Cancer Res. 2007. — Vol. 67. — P. 2643−2648.
- Outcomes in 45 pa tients with statin-associated myopathy / K. E. Hansen et al. // Arch Intern Med. 2005. — Vol. 165. — P. 2671−2676.
- Padala, К- P. Simvastatin-induced decline in cognition / K. P. Palada, P. R. Padala, J. F. Potter // Ann Pharmacother. 2006. — Vol. 40. — P. 1880−1883. -DOI 10.1345/aph.lH014.
- Parsons, L. S. Reducing bias in a propensity matched-pair sample using greedy matching techniques. Proceedings of the twenty-sixth annual SAS users group international conference / L. S. Parsons // Cary, NC: SAS Institute Inc. -2001.-P. 1214−1226.
- Peters, J. T. Behavioral changes with paranoia in an elderly woman taking atorvastatin / J. T. Peters, C. L. Garwood, M. Lepczyk // Am J Geriatr Pharmacother. 2008. — Vol. 6. — P. 28−32.
- Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease / M. Hu et al. // Curr Pharmacogenom Person Med. -2009. Vol. 7. — P. 1−26.
- Pharmacogenomic insights into treatment and management of statin-induced myopathy / B. J. Peters et al. // Genome Med. 2009. — Vol. 1. — P. 120.
- Pharmacological Management of Persistent Pain in Older Persons / American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons // JAGS. 2009. — V. 57. — P. 1331−1346.
- Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer / A. A. Adjei et al. // J Clin Oncol. 2003. -Vol. 21.-P. 1760−1766.
- Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer / S. Rao et al. // J Clin Oncol. 2004. — Vol. 22. — P. 3950−3957.
- Phillips, P. S. Balancing randomized trials with anecdote / P. S. Phillips // Ann Intern Med. 2009. — Vol. 150. — P. 885−886.
- Pravastatin and cognitive function in the elderly. Results of the PROSPER study / S. Trompet et al. // J Neurol. 2010. — Vol. 257. — P. 85−90.
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial / J. Shepherd et al. // Lancet. 2002. — Vol. 360. -P. 1623−1630.
- Preiss, D. Statins and the risk of new-onset diabetes: a review of recent evidence / D. Preiss, N. Sattar // Curr Opin Lipidol. 2011. — Vol. 22. — P. 460 466.
- Prevalence of musculoskeletal pain and statin use / C. Buettner et al. // J Gen Intern Med.-2008.-Vol. 23.-P. 1182−1186.
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia / J. Shepherd et al.- the West of Scotland Coronary Prevention Study Group // N Engl J Med. 1995. — Vol. 333. — P. 1301−1308.
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia / J. Shepherd et al. — West of Scotland Coronary Prevention Study Group // N Engl J Med. 1995. — Vol. 333. — P. 1301−1307.
- Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS / J. R. Downs et al. — for the AFCAPS/TexCAPS Research Group // J Am Med Assoc. 1998. — Vol. 279. — P. 1615−1622.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. -1994. Vol. 344. — P. 1383−1389.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvistatin Survival Study (4S) / Scandinavian Simvistatin Survival Study Group // Lancet. 1994. — Vol. 344. — P. 1383−1389.
- Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults / M. F. Muldoon et al. // Am J Med. 2004. — Vol. 117.-P. 823−829.-DOI 10.1016/j.amjmed.2004.07.041.
- Ray, G. M. Antiretroviral and statin drug-drug interactions / G. M. Ray // Cardiol Rev. 2009. — Vol. 17. — P. 44−47.
- Redelmeier, D. A. Delirium after elective surgery among elderly patients taking statins. / D. A. Redelmeier, D. Thiruchelvam, N. Daneman // CMAJ. -2008. Vol. 179. — P. 645−652.
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89 803 / Ng. Kimmie et al. // J Natl Cancer Inst. -2011.-Vol. 103.-P. 1540−1551.
- Rembold, C. M. Age predicts cancer incidence better than statin-induced low-density lipoprotein level / C. M. Rembold // J Am Coll Cardiol. 2008. -Vol. 51.-P. 90−91.
- Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment / Y. S. Chatzizisis et al. // Drug Saf. 2010. -Vol. 33.-P. 171−187.
- Risk of colorectal cancer in patients prescribed statins, nonsteroidal antiinflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study / Y. Vinogradova et al. // Gastroenterology. 2007. — Vol. 133. — P. 393102.
- Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis / D. Preiss et al. // JAMA. 2011. — Vol. 305. -P. 2556−2564.
- Risks associated with statin therapy: a systematic overview of randomized clinical trials / A. Kashani et al. // Circulation. 2006. — Vol. 114. — P. 27 882 797.
- Roberts, W. C. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs / W. C. // Am J Cardiol. 1997. — Vol. 80. — P. 106−107.
- Rodseth, R. Review: Perioperative statins reduce perioperative myocardial infarction and atrial fibrillation in statin-naive patients / R. Rodseth, P. J. Devereaux// Ann Intern Med. 2012. — Vol. 156. — JC6−2.
- Rojas-Fernandez, C. H. Is Statin-associated Cognitive Impairment Clinically Relevant? / C. H. Rojas-Fernandez, J. C. F. Cameron // The Annals of Pharmacotherapy. -2012. Vol. 46. — P. 549−557.
- Rosuvastatin in older patients with systolic heart failure / J. Kjekshus et al. // N Engl J Med. 2007. — Vol. 357. — P. 2248−2261.
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein / P. Ridker et al. // N Engl J Med. 2008. — Vol. 359. — P. 2195−2207.
- Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program / J. Shepherd et al. // Cardiology. 2007. -Vol. 107. — P. 43343.
- Saher, G. Cholesterol and myelin biogenesis / G. Saher, M. Simons // Subcell Biochem. -2010. Vol. 51. — P. 489−508.
- Sampson, U. K. Are statins diabetogenic? / U. K. Sampson, M. F. Linton, S. Fazio // Curr Opin Cardiol. 2011. — Vol. 26. — P. 342−347.
- Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update / M. Schachter// Fundam Clin Pharmacol. -2005. -Vol. 19.-P. 117−125.
- Sensitive sequencing method for KRAS mutation detection by pyrosequencing / S. Ogino et al. // J Mol Diagn. 2005. — Vol. 7. — P. 413121.
- Serum lipoprotein levels, statin use, and cognitive function in older women / K. Yaffe et al. // Arch Neurol. 2002. — Vol. 59. — P. 378−384.
- Sewright, K. A. Statin myopathy: incidence, risk factors, and pathophysiology / K. A. Sewright, P. M. Clarkson, P. D. Thompson // Curr Atheroscler Rep. 2007. — Vol. 9. — P. 389−396.
- Shepardson, N. E. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations / N. E. Shepardson, G. M. Shankar, D. J. Selkoe // Arch Neurol. 2011. — Vol. 68. — P. 1385−1392.
- Short-term memory loss associated with rosuvastatin / L. Galatti et al. // Pharmacotherapy. 2006. — Vol. 26. — P. 1190−1192.
- Sikka, R. Estimating medication persistency using administrative claims data / R. Sikka, F. Xia, R. E. Aubert // Am J Manag Care. 2005. — Vol. 11. — P.449.457.
- Silva, P. M. da. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin / P. M. da Silva // Am J Cardiovasc Drugs. 2011. -Vol. 11.-P. 93−107.
- Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation /
- A. Undas et al. // Circulation. -2001. Vol. 103. — P. 2248−2253.
- Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, controlled trial / L. Rejnmark et al. // Int J Endocrinol. 2010. — Vol. 2010, Article ID: 957 174. — 6 P
- Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study / J. Lee et al. // Cancer Chemother Pharmacol. 2009. — Vol. 64. — P. 657−663.
- Simvastatin reduces MMP-3 level in interleukin lbeta stimulated human chondrocyte culture / P. E. Lazzerini et al. // Ann Rheum Dis. 2004. — Vol. 63. -P. 867−869.
- Sinzinger, H. Muscular side effects of statins / H. Sinzinger, R. Wolfram,
- B. A. Peskar // J Cardiovasc Pharmacol. 2002. — Vol. 40. — P. 163−171.
- SLCOIBI polymorphism markedly affects the pharmacokinetics of simvastatin acid / M. K. Pasanen et al. // Pharmacogenet Genomics. 2006. -Vol. 16. — P. 873−879.
- SLC01B1 Variants and Statin-Induced Myopathy A Genomewide Study / The SEARCH Collaborative Group // N Engl J Med. — 2008. — Vol. 359, N 8. -P. 789−799.
- Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study / R. W. Thomsen et al. // Br J Clin Pharmacol. -2005. Vol. 60. — P. 534−542.
- Sol, A. I. del. Pravastatin: an evidence-based statin? / A. I. del Sol, P. W. Nanayakkara // Expert Opin Drug Metab Toxicol. 2008. — Vol. 4. — P. 821−825.
- Statin myopathy: A common dilemma not reflected in clinical trials / G. Fernandez et al. // Cleveland Clinic Journal of Medicine. 2011. — Vol. 78, N 6. — P. 393−403.
- Statin therapy inhibits remyelination in the central nervous system / V. E. Miron et al. // Am J Pathol. 2009. — Vol. 174. — P. 1880−1890.
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease / S. E. Nissen et al. // N Engl J Med. 2005. — Vol. 352, N 1. — P. 2938.
- Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study / E. D. Flick et al. // Drugs. 2009. — Vol. 69.-P. 1445−1457.
- Statin use and the risk of colorectal cancer: has recent evidence shifted our opinion? A meta-analysis involving more than 1.7 million participants /1. Ditah et al. // American College of Gastroenterology. 2010. — Abstract 383.
- Statin use in Canadians: trends, determinants and persistence / C. I. Neutel et al. // Can J Public Health. 2007. — Vol. 98. — P. 412116.
- Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study / S. Clockaerts et al. // Ann Rheum Dis. -2012. Vol. 71. — P. 642−647.
- Statin-associated memory loss: analysis of 60 case reports and review of the literature / L. R. Wagstaff et al. // Pharmacotherapy. 2003. — Vol. 23. — P. 871−880.
- Statin-associated myopathy with normal creatine kinase levels / P. S. Phillips et al. // Ann Intern Med. 2002. — Vol. 137. — P. 581−585.
- Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database / G. Moulis et al. // Lupus. 2012. — Vol. 21. — P. 885−889.
- Statins accelerate the onset of collagen type II-induced arthritis in mice / R. J. Vandebriel et al. // Arthritis Res Ther. 2012. — Vol. 14. — P. 90.
- Statins and all-cause mortality in high-risk primary prevention: a metaanalysis of 11 randomized controlled trials involving 65,229 participants / K. K. Ray et al. // Arch Intern Med. 2010. — Vol. 170. — P. 1024−1031
- Statins and cancer prevention / M. F. Demierre et al. // Nat Rev Cancer.2005.-Vol. 5.-P. 930−942.
- Statins and cancer risk: a literature-based meta-analysis and metaregression analysis of 35 randomized controlled trials / S. Bonovas et al. // J Clin Oncol. -2006. Vol. 24. — P. 4808−4817.
- Statins and cancer risk: a meta-analysis / K. M. Dale et al. // JAMA.2006.-Vol. 295.-P. 74−80.
- Statins and cognitive functioning in the elderly: a population-based study / J. Benito-Leon et al. // J Alzheimers Dis. 2010. — Vol. 21. — P. 95−102.
- Statins and intracerebral hemorrhage: a retrospective cohort study/ D. G. Hackam et al. // Arch Neurol. 2012. — Vol. 69. — P. 395.
- Statins and intracerebral hemorrhage: a retrospective cohort study / D. G. Hackam et al. // Arch Neurol. 2012. — Vol. 69. — P. 39−45.
- Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis / D. G. Hackam et al. // Circulation. 2011. — Vol. 124. — P. 2233−2242.
- Statins and Musculoskeletal Conditions, Arthropathies, and Injuries / I. Mansi et al. // JAMA Intern Med. 2013. — Vol. 173. — P. 1318−1326. -doi: 10.100 l/jamainternmed.2013.6184.
- Statins and Risk of Cancer: A Retrospective Cohort Analysis of 45,857 Matched Pairs From an Electronic Medical Records Database of 11 Million Adult Americans / C. Marelli et al. // J Am Coll Cardiol. 2011. — Vol. 58. — P. 530 537.
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials / N. Sattar et al. // Lancet. 2010. — Vol. 375. — P. 735 742.
- Statins and stroke / A. Bersano et al. // Curr Med Chem. 2008. — Vol. 15.-P. 2380−2392.
- Statins and stroke / M. Rodriguez-Yanez et al. // Ther Adv Cardiovasc Dis. 2008. — Vol. 2. — P. 157−166.
- Statins and the joint: multiple targets for a global protection? / P. E. Lazzerini et al. // Seminars in arthritis and rheumatism. 2011. — Vol. 40. — P. 430−446.
- Statins and the risk of colorectal cancer / J. N. Poynter et al. // N Engl J Med.-2005.-Vol. 352.-P. 2184−2192.
- Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients / S. Bonovas et al. // J Clin Oncol. -2007. Vol. 25. — P. 3462−3468.
- Statins and the risk of colorectal cancer: a meta-analysis of 22 observational studies / N. J. Samadder et al. // American College of Gastroenterology. 2010. — Abstract 1481.
- Statins have biphasic effects on angiogenesis / M. Weis et al. // Circulation. 2002. — Vol. 105. — P. 739−745.
- Statins in liver disease: a molehill, an iceberg, or neither? / C. K. Argo et al. // Hepatology. 2008. — Vol. 48. — P. 662−669.
- Statins, low-density lipoprotein cholesterol, and risk of cancer / A. Alsheikh-Ali et al. // J Am Coll Cardiol. 2008. — Vol. 52. — P. 1141−1147.
- Steinberg, D. Statin treatment does not cause cancer / D. Steinberg // J Am Coll Cardiol. 2008. — Vol. 52. — P. 1148−1149.
- Strandberg, T. E. Low low-density lipoprotein cholesterol and cancer risk / T. E. Strandberg // J Am Coll Cardiol. 2008. — Vol. 51. — P. 91−92.
- Tandra, S. Use of statins in patients with liver disease / S. Tandra, R. Vuppalanchi // Curr Treat Options Cardiovasc Med. 2009. — Vol. 11. — P. 272 278.
- Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence? / M. Attur et al. // Best Pract Res Clin Rheumatol. 2010. — Vol. 24. -P. 71−79.
- Taylor, M. L. Statins and cancer: a meta-analysis of case-control studies / M. L. Taylor, B. J. Wells, M. J. Smolak // Eur J Cancer Prev. 2008. — Vol. 17. -P. 259−268.
- The ABCG2 transporter and its relationswith the pharmacokinetics, drug interaction andlipid-lowering effects of statins / M. Hu et al. // Expert Opin Drug Metab Toxicol. 2011. — Vol. 7. — P. 49−62.
- The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study / S. P. Glasser et al. // Clin Cardiol. 2010. — Vol. 33. — P. 280−288.
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels / F. M. Sacks et al. // N Engl J Med. -1996. Vol. 335. — P. 1001−1009.
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease / S. Youssef et al. // Nature. 2002. — Vol. 420. — P. 78−84.
- The influence of SLCOIBI (OATP1B1) gene polymorphisms on response to statin therapy / S. P. Romaine et al. // Pharmacogenomies J. 2009. — Vol. 10.-P. 1−11.
- The Prospective Pravastatin Pooling (PPP) / R. P. Byington et al. // Project Circulation. 2001. — Vol. 103. — P. 387.
- The risk of cancer in users of statins / M. R. Graaf et al. // J Clin Oncol. -2004. Vol. 22. — P. 2388−2394.
- The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment / M. Fiegenbaum et al. J // Clin Pharmacol Ther. 2005. — Vol. 78. — P. 551−558.
- The SLC01B1*5 genetic variant is associated with statin-induced side effects / D. Voora et al. // J Am Coll Cardiol. 2009. — Vol. 54. — P. 16 091 616.
- Therneau, T. Modeling Survival Data: Extending the Cox Model / T. Therneau, P. Grambsch. New York: Springer, 2000.
- Thompson, P. D. An assessment of statin safety by muscle experts / P. D. Thompson, P. M. Clarkson, R. S. Rosenson // Am J Cardiol. 2006. — Vol. 97. -P. 69C-76C.
- Thompson, P. D. Statin-associated myopathy / P. D. Thompson, P. Clarkson, R. H. Karas // JAMA. 2003. — Vol. 289. — P. 1681−1690.
- Toth, P. P. Drug safety evaluation of rosuvastatin / P. P. Toth, T. D. Dayspring // Expert Opin Drug Saf 2011. — Vol. 10. — P. 969−986.
- Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? / D. D. Waters et al. // Am J Cardiol. 2004. -Vol. 93.-P. 154−158.
- Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial / D. W. McCarey et al. // Lancet. 2004. -Vol. 363.-P. 2015−2021.
- Ukomadu, С. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases / C. Ukomadu, A. Dutta // J Biol Chem. 2003. — Vol. 278. — P. 43 586−43 594.
- Understanding the Potential Role of Statins in Pneumonia and Sepsis / S. Yende et al. // Crit Care Med. 2011. — Vol. 39. — P. 1871−1878.
- Use of statins is associated with an increased risk of rheumatoid arthritis / H. J. de Jong et al. // Ann Rheum Dis. 2012. — Vol. 71. — P. 648−654.
- Users' guides to the medical literature. IV. How to use an article about harm/M. Levine et al.//JAMA. 1994. — Vol. 271.-P. 1615−1619.
- Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance / C. J. Glueck et al. //CurrMedRes Opin. -2011. Vol. 27. — P. 1683−1690.
- Vladutiu, G. D. Genetic predisposition to statin myopathy / G. D. Vladutiu // Curr Opin Rheumatol. 2008. — Vol. 20. — P. 648−655.
- Waters, D. D. Safety of high-dose atorvastatin therapy / D. D. Waters // Am J Cardiol. 2005. — Vol. 96. — 69F-75 °F.
- Weissert, R. Statins: A Revised Appraisal for Potential Additional Future Treatment Indications / R. Weissert // Arthritis Res Ther. 2012. — Vol. 14. — P. 121.
- WHO Collaborating Centre for Drug Statistic Methodology Электронный ресурс. // World Health Organization: [сайт]. Режим доступа: http://www.whocc.no/ (дата обращения: 10.10.12).
- WHO: World Health Statistics 2012 Электронный ресурс. 2012. -P.34.-Режим доступа: http://www.wlio. int/gho/publications/worldhealthstatistics/2012/en/ (дата обращения:05.01.2013).
- WHO: Global Health Observatory. Deaths from CVD and diabetes 2008 Электронный ресурс. // World Health Organization: [сайт]. Режим доступа: http://www.who.int/gho/ncd/mortalitymorbidity/cvd/en/index.litml (дата обращения: 10.10.12).
- Wilke, R. A. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage / R. A. Wilke, J. H. Moore, J. K. Burmester // Pharmacogenet Genomics. 2005. — Vol. 15. — P. 415−421.
- Wolfe, S. M. Dangers of rosuvastatin identified before and after FDA approval / S. M. Wolfe // Lancet. 2004. — Vol. 363. — P. 2189−2190.
- Wu, Y. Measuring follow-up completeness / Y. Wu, J. J. Takkenberg, G. L. Grunkemeier // Ann Thorac Surg. 2008. — Vol. 85. — P. 1155−1157.
- Zamor, P. J. Liver function tests and statins / P. J. Zamor, M. W. Russo // Curr Opin Cardiol. 2011. — Vol. 26. — P. 338−341.
- Zeliger, H. Statin use and risk of diabetes / H. Zeliger // Arch Internal Med. 2012. — Vol. 172, N 11. — P. 896−897.